Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Int Immunopharmacol. 2013 Aug 28;17(3):10.1016/j.intimp.2013.08.005. doi: 10.1016/j.intimp.2013.08.005

Figure 1.

Figure 1

Local intrarespiratory re-introduction of a recombinant Sema4A protein downregulates acute allergic airway inflammation in Sema4A−/− mice. Sema4A−/− mice were immunized with OVA as shown in Supplemental Figure S1 A. Recombinant Sema4A protein was delivered intranasally to the respiratory system 24 hours before the first OVA aerosol challenge. Note downregulatory effect of rSema4A on BAL macrophage and eosinophil numbers (A) and the extent of lung tissue inflammation (B). *,#p<0.05, macrophages and eosinophils, PBS vs rSema4A treated OVA-challenged Sema4A−/− mice, correspondingly. (C) Cytokine contents in 5× concentrated BALF were measured using the CBA proinflammatory cytokine and Th1/Th2/Th17 kits. Data are shown as the FlowJo generated dot plots for pooled samples from 2 mice in one of 2 representative experiments. (D) Single dose of rSema4A has no effect of lung resistance measured by an invasive (FlexiVent, SCIREQ) technique.